// App-Quantinova.ai

1225 : NVP-HDM201: cellular and in vivo profile of a novel highly potent and selective PPI inhibitor of p53-Mdm2

Researchers

Presenter

  • Sebastien Jeay

Principal Investigators

  • Stephane Ferretti

  • Pascal Furet

  • Bjoern Gruenenfelder

  • Vito Guagnano

  • Nelson Guerreiro

  • Ensar Halilovic

  • Francesco Hofmann

  • Joerg Kallen

  • Michelle Leonard

  • Robert Mah

  • Keiichi Masuya

  • Rita Ramos

  • Caroline Rynn

  • Stephan Ruetz

  • Therese Stachyra-Valat

  • Stefan Stutz

  • Andrea Vaupel

  • Jens Wuerthner

  • Philipp Holzer

Medical Centers

  • Novartis Institutes for BioMedical Research, Basel, Switzerland

  • Novartis Institutes for BioMedical Research, Inc, Cambridge, MA

Locations

  • United States

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • HDM 201

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved